Germany moves to lower drug prices
- Assessing the Impact of Global Price Interdependencies. Richter, Anke // PharmacoEconomics;2008, Vol. 26 Issue 8, p649
Documented launch delays and the ensuing debate over their underlying causes have focused on assessment from the individual country's perspective. Seen in a larger game theoretical framework this may cause problems, because although the countries see an individual game, the pharmaceutical firm...
- Just roiling along. Tieman, Jeff; Hallam, Kristen // Modern Healthcare;10/23/2000, Vol. 30 Issue 44, p8
Reports the reactions of pharmaceutical companies to the regulation of prescription drug prices in Maine. Reasons of pharmaceutical companies for contesting the law; Information on the lawsuit filed by the Pharmaceutical Research and Manufacturers of America.
- Prescription Drug Brouhaha. Adrianson, Alex W. // Consumers' Research Magazine;Sep2000, Vol. 83 Issue 9, p38
Focuses on the reaction of the pharmaceutical industry to the proposed law on drug prices in Maine. Lawsuit filed by the Pharmaceutical Research and Manufacturers of America; Overview of the law.
- Reforming Spain's pharmaceutical industry. Ruiz, Magdalena // BMJ: British Medical Journal (International Edition);5/6/89, Vol. 298 Issue 6682, p1206
Focuses on the reforms in the pharmaceutical industry in Spain. Introduction of a bill for the substitution of a prescribed drug with another with the same composition; Regulation of the production, quality control, distribution of drugs and pricing of drugs; Objectives of the bill.
- Health care purchasing at risk. Betz, Robert // Health Systems Review;Jan/Feb95, Vol. 28 Issue 1, p21
Comments on marketplace and government pressures on pharmaceutical pricing. Effects of prescription drug discounts on consumers, health care providers and insurers; Implications of Section 1555 of the Federal Acquisition Streamlining Act of 1994; Regulation of access to the General Services...
- AIDS Drugs & the Pharmaceutical Industry: A Need For Reform. Griffin, Mary T. // American Journal of Law & Medicine;1991, Vol. 17 Issue 4, p363
The pharmaceutical industry has long enjoyed substantial profits despite increased requirements for drug approval and various attempts to regulate the industry. Drug companies have avoided effective regulation by blaming high prices on the costs of research and development. The search for drugs...
- Bl and Lilly's Trajenta battle. // Pharmaceutical Executive;Nov2011, Vol. 31 Issue 11, p36
The article discusses the impact of the German pharmaceutical pricing reform program, Arzneimittelmarktneuordnungsgesetz (AMNOG), on new drugs, that motivated pharmaceutical firm Bl and Lilly to decide not to launch the Trajenta drug in Germany.
- India moves gently to liberalize drug industry. Jayaraman, K.S. // Nature;9/1/1994, Vol. 371 Issue 6492, p8
Reports on the Indian government's decision to liberalize the pharmaceutical industry. Lifting of price controls on several drugs; Greater foreign participation; Encouragement of Indian companies to invest in research.
- Pharmaceutical Industry. // Economic Review (05318955);Feb2001, Vol. 32 Issue 2, p37
Reports the economic development in pharmaceutical industry in Pakistan. Dependence of pharmaceutical industry on the government in terms of prices. Number of pharmaceuticals companies on the list of Karachi Stock Exchange in 1999; Total pretax profit of pharmaceuticals companies.